Nanjing Hicin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300584.SZ

Nanjing Hicin Pharmaceutical Co., Ltd. EBITDA Margin for the year ending December 31, 2023: 19.23%

Nanjing Hicin Pharmaceutical Co., Ltd. EBITDA Margin is 19.23% for the year ending December 31, 2023, a 20.28% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Nanjing Hicin Pharmaceutical Co., Ltd. EBITDA Margin for the year ending December 31, 2022 was 15.99%, a -75.34% change year over year.
  • Nanjing Hicin Pharmaceutical Co., Ltd. EBITDA Margin for the year ending December 31, 2021 was 64.84%, a 357.84% change year over year.
  • Nanjing Hicin Pharmaceutical Co., Ltd. EBITDA Margin for the year ending December 31, 2020 was 14.16%, a -9.59% change year over year.
  • Nanjing Hicin Pharmaceutical Co., Ltd. EBITDA Margin for the year ending December 31, 2019 was 15.67%, a -4.55% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300584.SZ

Nanjing Hicin Pharmaceutical Co., Ltd.

CEO Mr. Yuping Cao
IPO Date Jan. 12, 2017
Location China
Headquarters No.1 Hengfa Road
Employees 553
Sector Healthcare
Industries
Description

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.

StockViz Staff

February 4, 2025

Any question? Send us an email